Selected Tag: Biocon
Selected Tag: Biocon

US FDA Issues 5 Observations To Biocon Biologics’ Bengaluru Unit

BasisPoint Insight

September 5, 2025 at 6:26 AM IST


Biocon Raises ₹45 Billion Via QIP To Pare Debt, Meet Obligations

BasisPoint Insight

June 23, 2025 at 10:34 AM IST


Biocon Raises ₹45 Billion Via QIP At ₹330 Per Share, Closes Issue

BasisPoint Insight

June 20, 2025 at 9:42 AM IST


Biocon Opens ₹45 Billion QIP Issue At ₹340.20 Floor Price

BasisPoint Insight

June 17, 2025 at 10:13 AM IST


Biocon Gets DCGI Nod For Liraglutide Drug Substance, Product

BasisPoint Insight

June 3, 2025 at 10:54 AM IST


Biocon's Malaysia Insulin Supply Contract Extended By Six Months

BasisPoint Insight

May 23, 2025 at 10:29 AM IST


Biocon Biologics Secures US Deals For Stelara Biosimilar Yesintek

BasisPoint Insight

May 6, 2025 at 2:32 AM IST


Biocon To Raise Up To ₹45 Billion Through Equity, Debt Instruments

BasisPoint Insight

April 24, 2025 at 5:24 PM IST


Biocon Settles Litigation Over Yesafili

BasisPoint Insight

April 15, 2025 at 5:06 PM IST


Biocon Biologics Gets US FDA Nod For Cancer Drug Biosimilar 

BasisPoint Insight

April 10, 2025 at 8:49 AM IST